|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCAF6 |
Gene summary for DCAF6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCAF6 | Gene ID | 55827 |
| Gene name | DDB1 and CUL4 associated factor 6 | |
| Gene Alias | 1200006M05Rik | |
| Cytomap | 1q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q58WW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55827 | DCAF6 | P37T-E | Human | Esophagus | ESCC | 3.73e-26 | 4.00e-01 | 0.1371 |
| 55827 | DCAF6 | P38T-E | Human | Esophagus | ESCC | 7.50e-06 | 2.46e-01 | 0.127 |
| 55827 | DCAF6 | P39T-E | Human | Esophagus | ESCC | 2.27e-17 | 3.26e-01 | 0.0894 |
| 55827 | DCAF6 | P40T-E | Human | Esophagus | ESCC | 8.32e-19 | 4.33e-01 | 0.109 |
| 55827 | DCAF6 | P42T-E | Human | Esophagus | ESCC | 2.12e-24 | 6.24e-01 | 0.1175 |
| 55827 | DCAF6 | P44T-E | Human | Esophagus | ESCC | 3.55e-10 | 2.58e-01 | 0.1096 |
| 55827 | DCAF6 | P47T-E | Human | Esophagus | ESCC | 9.35e-19 | 4.31e-01 | 0.1067 |
| 55827 | DCAF6 | P48T-E | Human | Esophagus | ESCC | 2.05e-23 | 4.48e-01 | 0.0959 |
| 55827 | DCAF6 | P49T-E | Human | Esophagus | ESCC | 2.10e-22 | 1.68e+00 | 0.1768 |
| 55827 | DCAF6 | P52T-E | Human | Esophagus | ESCC | 1.43e-27 | 6.15e-01 | 0.1555 |
| 55827 | DCAF6 | P54T-E | Human | Esophagus | ESCC | 3.59e-26 | 5.88e-01 | 0.0975 |
| 55827 | DCAF6 | P56T-E | Human | Esophagus | ESCC | 1.86e-07 | 1.09e+00 | 0.1613 |
| 55827 | DCAF6 | P57T-E | Human | Esophagus | ESCC | 1.12e-19 | 3.61e-01 | 0.0926 |
| 55827 | DCAF6 | P61T-E | Human | Esophagus | ESCC | 5.57e-22 | 5.38e-01 | 0.099 |
| 55827 | DCAF6 | P62T-E | Human | Esophagus | ESCC | 5.26e-50 | 9.71e-01 | 0.1302 |
| 55827 | DCAF6 | P65T-E | Human | Esophagus | ESCC | 7.13e-23 | 3.19e-01 | 0.0978 |
| 55827 | DCAF6 | P74T-E | Human | Esophagus | ESCC | 8.44e-29 | 7.36e-01 | 0.1479 |
| 55827 | DCAF6 | P75T-E | Human | Esophagus | ESCC | 3.28e-19 | 4.22e-01 | 0.1125 |
| 55827 | DCAF6 | P76T-E | Human | Esophagus | ESCC | 8.88e-18 | 2.85e-01 | 0.1207 |
| 55827 | DCAF6 | P79T-E | Human | Esophagus | ESCC | 5.35e-25 | 4.79e-01 | 0.1154 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCAF6 | SNV | Missense_Mutation | c.1189N>G | p.Thr397Ala | p.T397A | Q58WW2 | protein_coding | tolerated(0.17) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DCAF6 | SNV | Missense_Mutation | novel | c.2701G>A | p.Glu901Lys | p.E901K | Q58WW2 | protein_coding | tolerated(0.09) | benign(0.266) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DCAF6 | SNV | Missense_Mutation | rs765173203 | c.584C>T | p.Thr195Met | p.T195M | Q58WW2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DCAF6 | SNV | Missense_Mutation | c.1258N>G | p.Gln420Glu | p.Q420E | Q58WW2 | protein_coding | tolerated_low_confidence(0.13) | benign(0.074) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DCAF6 | SNV | Missense_Mutation | c.190G>A | p.Glu64Lys | p.E64K | Q58WW2 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-D8-A1JH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | nolvadex | SD | |
| DCAF6 | SNV | Missense_Mutation | c.2393C>T | p.Pro798Leu | p.P798L | Q58WW2 | protein_coding | tolerated(0.15) | possibly_damaging(0.478) | TCGA-E2-A1L6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DCAF6 | insertion | Nonsense_Mutation | novel | c.2762_2763insAACTCTACTTTCTTA | p.Met921delinsIleThrLeuLeuSerTer | p.M921delinsITLLS* | Q58WW2 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DCAF6 | insertion | In_Frame_Ins | novel | c.2763_2764insCAAAAGAGTTTTTTCTTTATTGGTTTC | p.Met921_Leu922insGlnLysSerPhePhePheIleGlyPhe | p.M921_L922insQKSFFFIGF | Q58WW2 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DCAF6 | SNV | Missense_Mutation | rs745578537 | c.1244N>T | p.Ser415Phe | p.S415F | Q58WW2 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.837) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| DCAF6 | SNV | Missense_Mutation | c.1258C>G | p.Gln420Glu | p.Q420E | Q58WW2 | protein_coding | tolerated_low_confidence(0.13) | benign(0.074) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |